Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0206-21 55513-0206 Bevacizumab-awwb MVASI 100.0 mg/4mL, 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jun 27, 2025 In Use
55513-0326-21 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 21, 2025 In Use
00173-0808-05 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
00024-0654-01 00024-0654 Isatuximab Sarclisa 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Mar 2, 2020 In Use
66733-0958-23 66733-0958 Cetuximab Erbitux 2.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 2, 2007 In Use
55513-0956-21 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 1, 2025 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 28, 2019 In Use
69448-0015-05 69448-0015 Trastuzumab-strf HERCESSI 150.0 mg/7.4mL, 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 1, 2025 In Use
55513-0730-21 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Apr 15, 2025 In Use
70121-2702-01 70121-2702 Denosumab-mobz Boncresa 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Dec 23, 2025 In Use
55513-0132-21 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jul 1, 2025 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
00143-9166-01 00143-9166 Denosumab-qbde XTRENBO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
00173-0821-33 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 22, 2011 Aug 31, 2017 No Longer Used
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
63459-0103-10 63459-0103 Rituximab-abbs Truxima 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous May 4, 2020 In Use
63459-0305-47 63459-0305 TRASTUZUMAB HERZUMA Immunotherapy Monoclonal Antibody HER2 Mar 16, 2020 In Use
00143-9165-01 00143-9165 Denosumab-qbde ENOBY 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
61314-0240-63 61314-0240 Denosumab JUBBONTI 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 2, 2025 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec 18, 2014 In Use
72606-0012-01 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
55513-0164-01 55513-0164 Traztuzumab-anns, trastuzumab-anns Kanjinti Immunotherapy Monoclonal Antibody HER2 Intravenous Feb 1, 2023 Jun 30, 2025 No Longer Used
55513-0730-01 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Nov 18, 2010 In Use
50242-0051-21 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 26, 1997 In Use
71202-0012-10 71202-0012 Denosumab OSPOMYV 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 1, 2025 Oct 31, 2025 In Use

Found 12250 results — Export these results